Agonist-induced CXCR4 and CB2 Heterodimerization Inhibits Gα13/RhoA-mediated Migration

Abstract

G-protein-coupled receptor (GPCR) heterodimerization has emerged as a means by which alternative signaling entities can be created; yet, how receptor heterodimers affect receptor pharmacology remains unknown. Previous observations suggested a biochemical antagonism between GPCRs, CXCR4 and CB2 (CNR2), where agonist-bound CXCR4 and agonist-bound CB2 formed a physiologically nonfunctional heterodimer on the membrane of cancer cells, inhibiting their metastatic potential However, the reduced signaling entities responsible for the observed functional outputs remain elusive. This study now delineates the signaling mechanism whereby heterodimeric association between CXCR4 and CB2, induced by simultaneous agonist treatment, results in decreased CXCR4-mediated cell migration, invasion, and adhesion through inhibition of the Gα13/RhoA signaling axis. Activation of CXCR4 by its cognate ligand, CXCL12, stimulates Gα13 (GNA13), and subsequently, the small GTPase RhoA, which is required for directional cell migration and the metastatic potential of cancer cells. These studies in prostate cancer cells demonstrate decreased protein expression levels of Gα13 and RhoA upon simultaneous CXCR4/CB2 agonist stimulation. Furthermore, the agonist-induced heterodimer abrogated RhoA-mediated cytoskeletal rearrangement resulting in the attenuation of cell migration and invasion of an endothelial cell barrier. Finally, a reduction was observed in the expression of integrin α5 (ITGA5) upon heterodimerization, supported by decreased cell adhesion to extracellular matrices Taken together, the data identify a novel pharmacologic mechanism for the modulation of tumor cell migration and invasion in the context of metastatic disease. This study investigates a signaling mechanism by which GPCR heterodimerization inhibits cancer cell migration. .

Signaling transduction regulated by 5-hydroxytryptamine 1A receptor and orexin receptor 2 heterodimers

“…Considerable studies showed that the heterodimers formed by different GPCRs could affect the downstream signaling pathway [47][48][49]. In our current study, we also Figure 8-9).…”

Therapeutic targeting of HER2–CB 2 R heteromers in HER2-positive breast cancer

“…Thus, CB 1 R physically interacts with CB 2 R (25), serotonin (26), adenosine (22,27), opioid (28), orexin (29), and angiotensin (30) receptors, and with the cannabinoid-related orphan receptor GPR55 (31). CB 2 R, on the other hand, has been shown to form heteromers with GPR55 (32, 33) and CXCR4 (34,35). Although several RTK-RTK heteromers and GPCR-GPCR heteromers have been previously described, there are very few examples of physical interaction between RTKs and GPCRs yet.…”

The Endocannabinoid System: A Target for Cancer Treatment

“…In breast and prostate cancer cells, C-X-C chemokine receptor type 4 (CXCR4)-CB2 receptor heteromers regulate proliferation, adhesion, and invasion, thus metastatic potential. In this case, cannabinoids agonists of the CB2 receptor inhibit the effect of CXCR4 agonist, thus indirectly affect invasion [28,29]. In breast cancer, both CB2 receptor and human V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 2 (HER2) were up-regulated, constituting an indisputable hallmark of cancer.…”